RxDoctor Payments Data

Philip Dineen

Nurse Practitioner · Morganton, NCNPI 1972974988

Payments from drug & device makers

$3,898in general payments, 2019–2025

Across 213 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$568
  • E.r. Squibb & Sons, L.L.C.$526
  • AstraZeneca$523
  • Novartis$473
  • Merck$456
  • Johnson & Johnson$407
  • plus $945 from 9 others

What the payments were for

  • Food & beverage$3,87399%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,898 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$36,868
Medicare patients
214
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban437$365,513
EntrestoSacubitril/Valsartan206$197,258
XareltoRivaroxaban53$50,139
JardianceEmpagliflozin44$43,890
FarxigaDapagliflozin Propanediol58$36,790
Dofetilide18$9,607
Metoprolol Succinate318$3,062
Diltiazem 24hr Er (Cd)Diltiazem Hcl110$1,896
Spironolactone319$1,770
Atorvastatin Calcium289$1,650
Carvedilol278$1,478
Losartan Potassium179$1,387
Olmesartan Medoxomil51$1,235
Torsemide82$993
ClopidogrelClopidogrel Bisulfate100$774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$392$365,513437 claims
NovartisEntresto$473$197,258206 claims
Johnson & JohnsonXarelto$407$50,13953 claims
Boehringer IngelheimJardiance$224$43,89044 claims
AstraZenecaFarxiga$523$36,79058 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Morganton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →